F7

Alternative Names: Coagulation factor VII, Proconvertin, Serum prothrombin conversion accelerator, SPCA, Eptacog alfa, EC 3.4.21.21, F7.

Coagulation factor VII is an important vitamin K-dependent factor that plays a role in the process of blood clotting. It exists in the blood as an inactive form, which is activated by minor proteolysis by factors IXa, Xa, XIIa, or thrombin. Once activated, factor VII produces a heavy chain with a catalytic domain and a light chain with 2 EGF-like domains, held together by a disulfide bond. The presence of factor III and calcium ions further enhances the activation of the coagulation cascade by converting factor IX to factor IXa and/or factor X to factor Xa. Alternative splicing of factor VII results in the formation of 2 different transcripts. Defects in coagulation factor VII can lead to coagulopathy. Furthermore, factor VII plays a critical role in initiating the extrinsic pathway of blood coagulation. It can be converted into an active form (factor VIIa) by minor proteolysis caused by factors Xa, XIIa, IXa, or thrombin. Additionally, factor VIIa, in the presence of tissue factor and calcium, can also convert factor IX into factor IXa.

  •
  • Sku: PSB-pro-331-10µg
  • Vendor: ProSpec-Tany
$145.00 USD
Shipping calculated at checkout.

Contact us directly for international purchases.

Title
Report Product Listing Issue (e.g. Missing Data, or Questions)
Safety Data Sheet
UniProt Listing
NCBI Link

Product Details

Product Description

Recombinant Human Coagulation Factor VIIa, also known as rFVIIa, is a bioengineered protein used in the treatment of bleeding disorders, particularly in patients with hemophilia A or B. Belonging to the serine protease family, this therapeutic protein plays a crucial role in the blood clotting cascade by activating factors IX and X. With a molecular weight of approximately 50 kilodaltons, rFVIIa is administered intravenously to promote hemostasis and control bleeding episodes in individuals with coagulation deficiencies. Its mechanism of action involves binding to tissue factor, leading to the formation of activated factor X, which subsequently initiates clot formation at the site of injury.

Current Lead Time

7-14 Days

Product Specifications

Species
 Human
Expression System BHK cells (Baby Hamster Kidney Cells)
Purity 98% by SDS-PAGE
Activity
 The potency per mg was tested and found to be 50,000Units/mg. The potency per mg was tested and found to be 50,000Units/mg.
Activity Assay
Animal Component Free (ACF) No
Molecular Weight
 N/A
Structure Homodimer
Endotoxin Concentration
 Not Available
Purification Method Not Available
Form
 Lyophilized
Formulation The protein 1 mg/ml was lyophilized after from a sterile solution containing 10mg sucrose pH-6.

*For Research Use Only

Product Guarantee

If your product is within its expiration period, and has not performed according to expectations, fill out the sample return form. Return the unused sample frozen, with the auto generated packing slip to the address on the instructions. You will receive a full refund along with a replacement of the unused portion (inclusive of the failed test). Damages do not cover any additional costs incurred for failed experimentation. 

Amino Acid Sequence

Check Uniprot Link

Storage Instruction

Lyophilized Factor-VIIa although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution Factor-VIIa should be stored at 4°C between 2-7 days and for future use below -18°C. Please prevent freeze-thaw cycles.

Sample Prep Instruction

It is recommended to reconstitute the lyophilized Factor-VIIa in sterile 18MΩ-cm H2O not less than 100µg/ml, which can then be further diluted to other aqueous solutions.

References

Not Available
View full details

F7
SUBHEADING

Recently viewed products